The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...

The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...